PATENT CLAIM ANALYSIS

Application Number: 15888519
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-11
Patent Classification: ["514", "007200"]

Abstract:
Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA 1c  and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided.

Claim (Index 15):
A sustained release pharmaceutical composition, wherein the composition comprises an exendin analog, wherein the exendin analog is the amino acid sequence of any one of SEQ ID NOs: 2 and 9-142.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 88.0
- Lexical Diversity: 1.27586
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13708474', '13084757', '12298933', '11272488', '11584114']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8937977193241435
- 35 USC 102 Novelty (BERT): 0.7093483869657424
- Combined Prediction Score: 0.8753527860883035
- Mean Citation Score: 849.0850300000003
- Max Citation Score: 1108.6364
- Similarity Product: 751.0312590610029

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test